Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares changing hands.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Oramed Pharmaceuticals to a “hold” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Oramed Pharmaceuticals Trading Up 2.8%

The firm has a market capitalization of $131.74 million, a PE ratio of 2.63 and a beta of 1.34. The company has a fifty day moving average price of $3.26 and a two-hundred day moving average price of $2.71.

Oramed Pharmaceuticals Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORMP. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 2.7% during the 3rd quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock worth $8,361,000 after purchasing an additional 83,978 shares during the period. SB Capital Management Inc acquired a new position in Oramed Pharmaceuticals in the fourth quarter valued at $5,415,000. Marshall Wace LLP purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $738,000. Bank of America Corp DE boosted its stake in shares of Oramed Pharmaceuticals by 4.4% during the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after buying an additional 6,261 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Oramed Pharmaceuticals by 31.2% during the fourth quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock worth $223,000 after buying an additional 18,600 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.